BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare ... One is from a phase 1/2 study evaluating VX-522, a messenger RNA therapy that could treat ...

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare disease that affects only around 109,000 patients worldwide. Suzetrigine could open the door to a ...

According to InvestingPro analysis, the company stands as a prominent player in the Biotechnology industry, with a strong focus on cystic fibrosis (CF ... particularly the development of suzetrigine ...

The company is poised to expand its commercial presence with significant upcoming launches in the pain and cystic fibrosis ... Alyftrek and the potential of VX-522 could further solidify Vertex ...